Benzinga | Nov 9, 2020 08:07AM EST

Biohaven Pharmaceutical Q3 EPS $(3.27) Misses $(2.89) Estimate, Sales $17.66M Miss $19.84M Estimate

Biohaven Pharmaceutical (NYSE:BHVN) reported quarterly losses of $(3.27) per share which missed the analyst consensus estimate of $(2.89) by 13.15 percent. This is a 60.29 percent decrease over losses of $(2.04) per share from the same period last year. The company reported quarterly sales of $17.66 million which missed the analyst consensus estimate of $19.84 million by 10.97 percent.